Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGX1321 in Advanced Gastrointestinal Tumors
NCT03507998Phase 1Unknown
- Sponsor
- Curegenix
- Start
- Jun 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CGX1321 in colorectal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma (PDAC) and 3 more, sponsored by Curegenix. Primary endpoint: Number of participants with adverse events and/or abnormal laboratory values that are related to treatment at 21 months. Status: unknown.
02
Drugs
CGX1321
03
Conditions
colorectal adenocarcinomagastric adenocarcinomapancreatic adenocarcinoma (PDAC)cholangiocarcinomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03507998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03507998.